Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group

Table 3

NET protein expression composite score (𝑛=61) according to baseline patient characteristics.

	𝑁	Median NET protein expression composite score (range)
Age ≤ 18 months	32	95 (0–300)
Age > 18 months	29	140 (0–300)
Intermediate-risk group	34	160 (0–300)**
High-risk group	27	60 (0–300)
Localized tumor	29	160 (0–300)**
Metastatic tumor	32	55 (0–300)
Adrenal primary tumor	28	100 (0–300)
Nonadrenal primary tumor	33	100 (0–300)
MYCN nonamplified	48	160 (0–300)***
MYCN amplified	13	10 (0–140)
Favorable histology	36	160 (0–300)
Unfavorable histology	24	70 (0–300)
Normal urine catecholamines^a	10	65 (0–240)
Elevated urine catecholamines	17	60 (0–300)

aAvailable only for patients with high-risk disease.
** 𝑃<0.05 for difference in expression between clinical groups.
*** 𝑃<0.001 for difference in expression between clinical groups.